T/R potency <5% [Regulatives / Guidelines]

posted by jag009  – NJ, 2022-09-08 21:54 (152 d 01:38 ago) – Posting: # 23281
Views: 1,145

❝ It was there in 2001 guidance as desired requirement-not mandatory... problem is that I can not find that 2001 (first) BE/BA guidance

❝ I can not find that 2001 (first) BE/BA guidance. Also in 2021 guidance lines 807-808


Correct the "should be within 5%" does exist in the FDA guidance (not the BE guidance for individual products). I was asked to provide the info last yr in a meeting...

John

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
23 visitors (0 registered, 23 guests [including 10 identified bots]).
Forum time: 22:33 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5